Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date May 04, 2026 · Filed May 04, 2026
Section 16 reporting ended · disclosed 2026-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 83,495 |
Reported balance
Holding disclosure · report date 2026-05-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 83,495 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 11:29 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $224.31 | $224,310.00 |
DisclosureSEC source: 0000943819-26-000020 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:29 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $254.30 | $254,300.00 |
DisclosureSEC source: 0000943819-26-000013 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 20:06 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $257.03 | $257,030.00 |
DisclosureSEC source: 0000943819-26-000008 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:27 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $241.75 | $241,750.00 |
DisclosureSEC source: 0000943819-26-000002 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:23 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $244.16 | $244,160.00 |
DisclosureSEC source: 0000943819-25-000184 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 15:45 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 2,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000171 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,495 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:02 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 2,000 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000092 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 2,000 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:02 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $247.54 | $742,620.00 |
DisclosureSEC source: 0000943819-25-000092 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,745 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:02 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 2,000 | $101.64 | $203,280.00 |
DisclosureSEC source: 0000943819-25-000092 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 16:56 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 2,000 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000084 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Underlying: ResMed Common Stock · 2,000 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 16:56 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $274.36 | $823,080.00 |
DisclosureSEC source: 0000943819-25-000084 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,745 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 16:56 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 2,000 | $101.64 | $203,280.00 |
DisclosureSEC source: 0000943819-25-000084 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:39 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 2,000 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000052 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 Underlying: ResMed Common Stock · 2,000 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:39 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $270.77 | $812,310.00 |
DisclosureSEC source: 0000943819-25-000052 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,745 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:39 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 2,000 | $101.64 | $203,280.00 |
DisclosureSEC source: 0000943819-25-000052 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 18:50 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 5,462 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000040 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,745 F1 · kind: Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 16:16 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 2,000 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000032 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: ResMed Common Stock · 2,000 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 16:16 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $281.90 | $845,700.00 |
DisclosureSEC source: 0000943819-25-000032 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,283 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 16:16 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 2,000 | $101.64 | $203,280.00 |
DisclosureSEC source: 0000943819-25-000032 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:53 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 917 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000025 · form4.xml · derivative · entry 5 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Underlying: ResMed Common Stock · 917 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:53 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 1,966 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000025 · form4.xml · derivative · entry 4 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,917 Underlying: ResMed Common Stock · 1,966 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:53 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,883 | $256.99 | $997,892.17 |
DisclosureSEC source: 0000943819-25-000025 · form4.xml · nonDerivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,283 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:53 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 917 | $101.64 | $93,203.88 |
DisclosureSEC source: 0000943819-25-000025 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 21:53 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 1,966 | $101.64 | $199,824.24 |
DisclosureSEC source: 0000943819-25-000025 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 21:59 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $243.78 | $243,780.00 |
DisclosureSEC source: 0000943819-25-000011 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,283 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| May 22, 2025 Filed May 27, 2025 14:24 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,644 | $244.59 | $891,285.96 |
DisclosureSEC source: 0001127602-25-015607 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,283 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. F2 · balance_after: Includes 62.6994 shares of ResMed stock purchased on April 30, 2025, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 22:14 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $215.58 | $215,580.00 |
DisclosureSEC source: 0001127602-25-011925 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 01:56 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $230.36 | $230,360.00 |
DisclosureSEC source: 0001127602-25-009188 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 17:55 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $238.98 | $238,980.00 |
DisclosureSEC source: 0001127602-25-004042 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:52 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $234.04 | $234,040.00 |
DisclosureSEC source: 0001127602-25-001067 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 18:17 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $244.23 | $244,230.00 |
DisclosureSEC source: 0001127602-24-029095 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:33 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $249.00 | $249,000.00 |
DisclosureSEC source: 0001127602-24-027030 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. F2 · balance_after: Includes 51.807 shares of ResMed stock purchased on October 31, 2024, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| October 08, 2024 Filed Oct 9, 2024 20:38 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $233.47 | $233,470.00 |
DisclosureSEC source: 0001127602-24-025369 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,812 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 01:18 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $246.42 | $246,420.00 |
DisclosureSEC source: 0001127602-24-023758 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,812 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 14:21 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 841 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022304 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,812 F2 · kind: Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on August 15, 2024, when the compensation committee certified that the performance metrics were met for this portion ofthegrant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 14:21 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 7,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022304 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,971 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on August 15, 2024, when the compensation committee certified that the performance metrics were met. Stock unitsvest1/3each year on the anniversary of the grant. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 15:57 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $212.16 | $212,160.00 |
DisclosureSEC source: 0001127602-24-021984 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,056 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 21:27 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $194.35 | $194,350.00 |
DisclosureSEC source: 0001127602-24-020248 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,056 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 21:05 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,000 | $209.81 | $209,810.00 |
DisclosureSEC source: 0001127602-24-018379 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,056 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. F2 · balance_after: Includes 94.177 shares of ResMed stock purchased on April 30, 2024, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 08, 2024 Filed May 10, 2024 19:21 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 12,000 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-24-014978 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,883 Underlying: ResMed Common Stock · 12,000 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 8, 2024. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 08, 2024 Filed May 10, 2024 19:21 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 13,000 | $211.37 | $2,747,810.00 |
DisclosureSEC source: 0001127602-24-014978 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,056 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 8, 2024. Read SEC document |
| May 08, 2024 Filed May 10, 2024 19:21 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 12,000 | $101.64 | $1,219,680.00 |
DisclosureSEC source: 0001127602-24-014978 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 8, 2024. F2 · balance_after: Includes 94.177 shares of ResMed stock purchased on April 30, 2024, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 27, 2023 Filed Nov 30, 2023 00:45 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,000 | $152.62 | $457,860.30 |
DisclosureSEC source: 0001127602-23-028436 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,962 F1 · balance_after: Includes 47.925 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:03 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 4,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022927 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,915 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| May 10, 2023 Filed May 12, 2023 23:30 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 12,574 | $233.13 | $2,931,395.48 |
DisclosureSEC source: 0001127602-23-015482 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,942 F1 · kind: The transaction was conducted during an open trading window. Read SEC document |
| May 09, 2023 Filed May 10, 2023 21:16 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,426 | $232.05 | $794,999.87 |
DisclosureSEC source: 0001127602-23-015146 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,516 F1 · kind: The transaction was conducted during an open trading window. F2 · balance_after: Includes 62.3215 shares of ResMed stock purchased on April 28, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:21 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 10,000 | $215.22 | $2,152,196.00 |
DisclosureSEC source: 0001127602-23-006460 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,880 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $215.00 - $215.59. The price reported above reflects the weighted average sale price. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 18:53 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,000 | $215.00 | $860,000.00 |
DisclosureSEC source: 0001127602-23-005095 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,880 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 22:56 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 14,577 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026356 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,880 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:03 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,000 | $212.02 | $848,067.60 |
DisclosureSEC source: 0001127602-22-025209 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,303 F1 · price: This transaction was executed in multiple trades at prices ranging from $212 to $212.04. The price reported above reflects the weighted average sale price. F2 · balance_after: Includes 30.50 shares of ResMed stock purchased on October 31, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.